bluebird bio stock falls after reverse split and capital raise reshape the balance sheet

bluebird bio Inc. (ISIN US1011371077) has seen bluebird bio stock trade through a year of financial restructuring, including a reverse stock split and fresh equity financing, as the Nasdaq-listed gene therapy company works to support commercial launches and manage its cash position.

Reverse split ten-for-one

According to a corporate action notice filed with Nasdaq on 4 September 2024, bluebird bio implemented a ten-for-one reverse stock split of its common shares, consolidating every 10 existing shares into 1 new share to remain compliant with listing requirements and improve price visibility for investors.

In the subsequent months, as of late 2024, shares continued to trade under the ticker NASDAQ: BLUE, reflecting the post-split structure and giving the market a clearer view of the company’s valuation relative to its gene therapy peers.

Capital raise of approximately $150 million

To strengthen its balance sheet and fund operations, bluebird bio disclosed a public equity offering in late 2024 with gross proceeds in the region of $150 million, issuing new common shares to institutional and retail investors at a discount to the prevailing market price and increasing the share count.

The new capital, combined with existing cash and equivalents, lifted the company’s total liquidity to several hundred million dollars as of the close of fiscal 2024, giving management additional resources to support commercialization and post-approval studies for its therapies while navigating the path to potential profitability.

Revenue growth from approved therapies

bluebird bio reported rising product revenue in fiscal 2024 as its gene therapy portfolio advanced, with total revenue moving from a low double-digit million dollar level in 2023 to a higher double-digit base in 2024, driven primarily by early commercial traction in severe genetic disease indications.

Compared with the prior year, this represented a percentage increase comfortably above fifty percent, illustrating that while the absolute revenue level remains modest relative to larger biopharmaceutical companies, the growth rate for bluebird bio’s approved therapies is beginning to reflect increased uptake in target populations and the impact of new market launches.

Net loss widens year on year

Despite the revenue improvement, bluebird bio’s net loss widened in fiscal 2024 compared with 2023, as higher research and development expenses and commercialization costs outweighed the increase in top-line performance.

The company’s net loss climbed from the mid-hundreds of millions of dollars in 2023 to a higher figure in 2024, underlining the scale of investment required to bring gene therapies through development and into routine clinical use, and highlighting that cash burn remains a central factor for bluebird bio stock sentiment.

Cash and cash equivalents support runway

At the end of fiscal 2024, bluebird bio reported a cash and cash equivalents position in the low-to-mid hundreds of millions of dollars, reflecting both its prior financing activity and the proceeds from the latest capital raise.

This cash balance, combined with expected revenue from commercial products, provides a funding runway that management has described as sufficient to cover key milestones in the near term, although the exact duration of the runway remains subject to variables such as trial timelines, regulatory decisions and the pace of market adoption.

Vector-based gene therapy leads the portfolio

bluebird bio’s core business focuses on vector-based gene therapies that deliver functional copies of genes to patients with severe inherited disorders, using technologies such as lentiviral vectors to achieve durable expression in blood-forming cells.

One of its representative therapies targets transfusion-dependent beta-thalassemia, aiming to reduce or eliminate the need for chronic red blood cell transfusions by enabling patients to produce sufficient hemoglobin following a single administration procedure.

For investors, the performance of these therapies in real-world settings and the pace at which treatment centers adopt them are pivotal for the long-term trajectory of bluebird bio’s revenue and margin profile, particularly given the high upfront costs and complex logistics associated with gene therapy.

bluebird bio stock and recent trading levels

On Nasdaq, bluebird bio stock continues to trade under the symbol BLUE, with the share price reflecting both the reverse split adjustment and ongoing shifts in investor expectations about the path to profitability and regulatory progress.

The stock has fluctuated within a wide range over the past twelve months, with levels that place the market capitalization in the hundreds of millions of dollars, far below the multibillion dollar valuation the company once commanded during earlier phases of gene therapy enthusiasm.